哺乳類細胞バンキングの世界市場

哺乳類細胞バンキングの世界市場は2030年までに11億米ドルに達する見込み

2024年に4億8,260万米ドルと推定される哺乳類細胞バンキングの世界市場は、2024年から2030年にかけてCAGR 14.0％で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるTEP技術は、CAGR13.2％を記録し、分析期間終了時には6億2,180万米ドルに達すると予測されます。IEP技術セグメントの成長率は、分析期間中CAGR 15.9％と推定されます。

米国市場は1億3,150万米ドルと推定、中国はCAGR18.5％で成長予測

米国の哺乳類細胞バンキング市場は、2024年に1億3,150万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR18.5%で推移し、2030年には2億2,490万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.4%と12.5%と予測されています。欧州では、ドイツがCAGR 11.1%で成長すると予測されています。

世界の哺乳類細胞バンキング市場- 主要動向と促進要因のまとめ

哺乳類細胞バンキングがバイオ医薬品開発・製造の要となる理由とは？

哺乳類細胞バンキングは、遺伝子的に一貫性があり、汚染のない細胞株を保存・再生産する役割を果たすため、バイオ医薬品の開発と商業生産において不可欠な柱となっています。これらの細胞バンクは、モノクローナル抗体、組換えタンパク質、ワクチン、遺伝子治療などの複雑な生物学的製剤を製造するための基盤となる供給源として機能しています。微生物システムとは異なり、哺乳類細胞は多くの生物製剤の治療効果と安定性に不可欠な、複雑な翻訳後修飾を行うことができるユニークな細胞です。生物製剤に対する世界の需要が増加し続ける中、製品の一貫性と安全性を保証する、十分に特性化され安定した細胞株の重要性は飛躍的に高まっています。マスター・セル・バンク（MCB）とワーキング・セル・バンク（WCB）は、厳格な規制要件に準拠しつつ、大規模生産における再現性を保証するために、適正製造基準（GMP）の下で細心の注意を払って作成されます。適切な保管、文書化、トレーサビリティは、細胞バンク業務において重要な要素です。バイオ医薬品のパイプラインが、より標的を絞った個別化治療で拡大するにつれ、哺乳類細胞バンキングの役割も、自家細胞療法や同種細胞療法のサポートへと広がっています。強固な細胞バンクを確立する戦略的価値は、長期的な開発リスクの軽減、スケールアップの合理化、規制当局の監査や製品回収への迅速な対応にあります。これらの機能により、生物製剤の初期段階の調査から本格的な商業生産に至るまで、なぜ情勢が不可欠なのかが明らかになります。

技術革新は、細胞培養プロセスの効率性と信頼性をどのように高めているか？

バイオプロセス技術、自動化、分析における進歩は、哺乳類細胞バンキング操作の精度、拡張性、信頼性を著しく向上させています。制御された凍結速度や凍結保護剤の最適化などの凍結保存技術における革新は、細胞の生存率や解凍後の遺伝的安定性を向上させており、これはマスター細胞バンクとワーキング細胞バンクの両方の完全性を長期にわたって維持するために不可欠です。細胞培養、採取、分注プロセスの自動化は、操作のスループットと一貫性を高めながら、汚染や人為的ミスのリスクを軽減します。最新のバイオバンク施設では、無菌処理をサポートし、手作業による介入を最小限に抑えるために、ロボット工学やクローズドシステム技術の活用が進んでいます。さらに、次世代シーケンシングやリアルタイムPCRのような高度な分析は、細胞株を徹底的に特徴付け、不定胞子、マイコプラズマ、遺伝子ドリフトがないことを確認するために適用されています。人工知能と機械学習は、バイオバンクの予知保全と品質予測に役割を果たし始めており、施設は動向を監視し、製品の完全性が損なわれる前に機器や生存性の問題を先制することができます。クラウドベースのデータ管理プラットフォームは、記録の一元化、施設間のリアルタイムのコラボレーションを可能にし、完全なトレーサビリティで規制当局の監査をサポートするために採用されています。これらのテクノロジーは、オペレーションを合理化するだけでなく、FDA、EMA、ICHなどの規制機関による進化する国際基準へのコンプライアンスを強化します。その結果、企業は高水準の品質と再現性を維持しながら、市場投入までの時間を大幅に短縮することができ、技術的に高度な哺乳類細胞バンキングシステムへの投資の戦略的重要性が強化されます。

世界の哺乳類細胞バンキングサービスの需要を形成している業界動向とは？

様々な業界動向が、特に生物製剤や細胞ベースの治療が現代医学の中心になるにつれて、世界中で哺乳類細胞バンキングサービスの需要を高めています。モノクローナル抗体、バイオシミラー、個別化医薬品の需要の急増は、大手バイオ製薬会社と開発・製造受託機関（CDMO）の双方に、スケーラブルで信頼性の高い細胞バンキング・インフラへの投資を促しています。細胞・遺伝子治療パイプラインの急速な拡大も、厳格な品質管理のもとで自家・同種ワークフローをサポートできる、カスタマイズされたセルバンキング・ソリューションの必要性を高めています。さらに、バイオ医薬品の技術革新が希少疾患や希少疾病用医薬品へと拡大するにつれて、企業は厳格な規制と安全性のベンチマークを満たさなければならない、より小規模で高度に専門化された細胞株のバンキングをますます行うようになっています。生物製剤製造の世界化に伴い、分散型製造モデルをサポートし、サプライチェーンの弾力性を向上させ、地域の規制要件を満たすために、地域ごとの細胞バンク施設の設立が進んでいます。一方、バイオテクノロジー分野における新興企業や学術研究機関の台頭は、ターンキー型の細胞バンキング・ソリューションを提供する第三者サービス・プロバイダーの成長に拍車をかけています。これらのサービスには、凍結保存や保管だけでなく、細胞株の特性解析、文書化、規制当局のサポートなども含まれます。アウトソーシングや提携モデルへのシフトにより、中小企業は大規模な資本投資をすることなく、高品質のインフラを利用できるようになっています。バイオ医薬品業界がデータ主導型になるにつれ、生物学的保存とデジタルモニタリング、コンプライアンス追跡、分析を組み合わせた統合ソリューションへの需要が高まっています。これらの動向が相まって、世界の哺乳類細胞バンキング市場の範囲と規模が拡大しています。

世界の哺乳類細胞バンキング市場の成長を促進する要因は？

世界の哺乳類細胞バンキング市場の成長は、バイオ医薬品の拡大、規制遵守、技術進歩に関連するいくつかの重要な要因によって牽引されています。主な促進要因の一つは、臨床開発および商業化に入るバイオ医薬品、特に発現に哺乳類系を必要とする複雑な生物製剤の数が増加していることです。治療用タンパク質の生産において、チャイニーズハムスター卵巣（CHO）細胞やその他の哺乳類宿主への依存が高まっていることは、堅牢でコンプライアンスに準拠したセルバンキングシステムの必要性に直結しています。バイオセーフティ、トレーサビリティ、製品の一貫性に関する規制当局の期待はますます厳しくなっており、バイオファーマ企業は高品質の細胞バンク施設とサービスへの投資を余儀なくされています。さらに、特に腫瘍学と再生医療における個別化医療の成長は、慎重に管理された条件下で保存・管理されなければならない患者固有の細胞株に対する需要を生み出しています。専門的な細胞バンクサービスを提供するCDMOの拡大により、企業は事業規模を拡大しやすくなり、世界市場に迅速に参入できるようになっています。さらに、バイオマニュファクチャリングにおける政府の資金援助や官民パートナーシップの拡大が、インフラ整備を支援し、GMPグレードのバイオバンキング手法の採用を促しています。幹細胞療法、免疫療法、CRISPRのような遺伝子編集プラットフォームを含む臨床試験の増加も、安全でスケーラブルな哺乳類細胞保存の必要性に寄与しています。凍結保存、デジタル・トラッキング、細胞株認証の技術的進歩は、インハウスとアウトソーシングの両方の細胞バンキング・ソリューションの価値提案を強化しています。これらの要因を総合すると、哺乳類細胞バンキングは生物製剤の開発、製造、商業化の将来における基礎的要素として位置づけられています。

セグメント

技術（TEP技術、IEP技術、SEP技術）、用途（MCB用途、WCB用途、EoP用途、R&D CB用途）、最終用途（学術・研究機関最終用途、バイオ医薬品企業最終用途、CRO最終用途）

調査対象企業の例

• 3P Biopharmaceuticals
• Advanced Therapies
• Becton, Dickinson and Company（BD）
• Charles River Laboratories
• Corning Incorporated
• Cryo-Cell International
• Danaher Corporation
• Eppendorf AG
• Eurofins DiscoverX/SwissBio
• Fujifilm Irvine Scientific
• GE Healthcare Life Sciences（Cytiva）
• InvivoGen
• Lonza Group Ltd
• Merck KGaA（MilliporeSigma）
• Sartorius AG
• Sigma-Aldrich Corporation
• SCTbio
• Takara Bio Inc.
• Thermo Fisher Scientific
• WuXi AppTec/WuXi Biologics
• Cedarlane Laboratories

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Mammalian Cell Banking Market to Reach US$1.1 Billion by 2030

The global market for Mammalian Cell Banking estimated at US$482.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. TEP Technology, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$621.8 Million by the end of the analysis period. Growth in the IEP Technology segment is estimated at 15.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$131.5 Million While China is Forecast to Grow at 18.5% CAGR

The Mammalian Cell Banking market in the U.S. is estimated at US$131.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$224.9 Million by the year 2030 trailing a CAGR of 18.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.4% and 12.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global Mammalian Cell Banking Market - Key Trends & Drivers Summarized

Why Is Mammalian Cell Banking a Cornerstone in Biopharmaceutical Development and Manufacturing?

Mammalian cell banking has become an essential pillar in the development and commercial production of biopharmaceuticals due to its role in preserving and reproducing genetically consistent and contamination-free cell lines. These cell banks serve as the foundational source for producing complex biological products such as monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. Unlike microbial systems, mammalian cells are uniquely capable of performing intricate post-translational modifications, which are critical for the therapeutic efficacy and stability of many biologics. As the global demand for biologics continues to rise, the importance of well-characterized and stable cell lines that ensure product consistency and safety has grown exponentially. Master cell banks (MCBs) and working cell banks (WCBs) are meticulously created under Good Manufacturing Practices (GMP) to guarantee reproducibility in large-scale production while complying with stringent regulatory requirements. Proper storage, documentation, and traceability are critical components of cell banking operations, as any variation can lead to costly delays, failed batches, or compromised patient safety. As biopharma pipelines expand with more targeted and personalized therapies, the role of mammalian cell banking is also broadening to include support for autologous and allogeneic cell therapies. The strategic value of establishing robust cell banks lies in reducing long-term development risks, streamlining scale-up, and enabling faster response to regulatory audits and product recalls. These capabilities highlight why mammalian cell banking is indispensable for both early-stage research and full-scale commercial production across the biologics landscape.

How Are Technological Innovations Enhancing the Efficiency and Reliability of Cell Banking Processes?

Advancements in bioprocessing technologies, automation, and analytics are significantly enhancing the precision, scalability, and reliability of mammalian cell banking operations. Innovations in cryopreservation techniques, such as controlled-rate freezing and cryoprotectant optimization, are improving cell viability and genetic stability post-thaw, which is critical for preserving the integrity of both master and working cell banks over time. Automation in cell culture, harvesting, and aliquoting processes reduces the risk of contamination and human error while boosting operational throughput and consistency. Modern biobanking facilities are increasingly utilizing robotics and closed-system technologies to support sterile processing and minimize manual interventions. In addition, advanced analytics such as next-generation sequencing and real-time PCR are being applied to thoroughly characterize cell lines, ensuring they are free from adventitious agents, mycoplasma, and genetic drift. Artificial intelligence and machine learning are beginning to play a role in predictive maintenance and quality forecasting for biobanks, allowing facilities to monitor trends and preempt equipment or viability issues before they compromise product integrity. Cloud-based data management platforms are being adopted to centralize records, enable real-time collaboration across sites, and support regulatory audits with full traceability. These technologies not only streamline operations but also enhance compliance with evolving international standards from regulatory bodies such as the FDA, EMA, and ICH. As a result, companies can significantly reduce time to market while maintaining high standards of quality and reproducibility, thereby reinforcing the strategic importance of investing in technologically advanced mammalian cell banking systems.

What Industry Trends Are Shaping the Demand for Mammalian Cell Banking Services Globally?

A variety of industry trends are contributing to increased demand for mammalian cell banking services across the globe, especially as biologics and cell-based therapies become central to modern medicine. The surge in demand for monoclonal antibodies, biosimilars, and personalized medicines is prompting both large biopharmaceutical firms and contract development and manufacturing organizations (CDMOs) to invest in scalable and reliable cell banking infrastructure. The rapid expansion of cell and gene therapy pipelines is also driving a need for customized cell banking solutions that can support autologous and allogeneic workflows under rigorous quality controls. Additionally, as biopharmaceutical innovation expands into rare diseases and orphan drugs, companies are increasingly banking smaller, highly specialized cell lines that must meet strict regulatory and safety benchmarks. The globalization of biologics manufacturing is leading to the establishment of regional cell banking facilities to support decentralized production models, improve supply chain resilience, and meet local regulatory requirements. Meanwhile, the rise of start-ups and academic research institutions in the biotech space is fueling the growth of third-party service providers offering turnkey cell banking solutions. These services include not only cryopreservation and storage but also cell line characterization, documentation, and regulatory support. The shift toward outsourcing and partnership models is enabling smaller players to access high-quality infrastructure without large capital investments. As the biopharma industry becomes more data-driven, demand is growing for integrated solutions that combine biological storage with digital monitoring, compliance tracking, and analytics. Together, these trends are expanding the scope and scale of the global mammalian cell banking market.

What Factors Are Driving Growth in the Global Mammalian Cell Banking Market?

The growth in the global mammalian cell banking market is driven by several critical factors related to biopharmaceutical expansion, regulatory compliance, and technological progress. One of the primary drivers is the rising number of biopharmaceutical products entering clinical development and commercialization, especially complex biologics that require mammalian systems for expression. The increasing reliance on Chinese Hamster Ovary (CHO) cells and other mammalian hosts for producing therapeutic proteins is directly tied to the need for robust and compliant cell banking systems. Regulatory expectations around biosafety, traceability, and product consistency are becoming more stringent, compelling biopharma companies to invest in high-quality cell banking facilities and services. Additionally, the growth of personalized medicine, particularly in oncology and regenerative medicine, is creating demand for patient-specific cell lines that must be stored and managed under carefully controlled conditions. Expansion of CDMOs offering specialized cell banking services is making it easier for companies to scale operations and enter global markets more quickly. Furthermore, increased government funding and public-private partnerships in biomanufacturing are supporting infrastructure development and encouraging adoption of GMP-grade biobanking practices. The rise in clinical trials involving stem cell therapies, immunotherapies, and gene editing platforms such as CRISPR is also contributing to the need for secure and scalable mammalian cell storage. Technological advances in cryopreservation, digital tracking, and cell line authentication are enhancing the value proposition for both in-house and outsourced cell banking solutions. Collectively, these factors are positioning mammalian cell banking as a foundational element in the future of biologics development, manufacturing, and commercialization.

SCOPE OF STUDY:

The report analyzes the Mammalian Cell Banking market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (TEP Technology, IEP Technology, SEP Technology); Application (MCB Application, WCB Application, EoP Application, R&D CB Application); End-Use (Academic & Research Institute End-Use, Biopharma Companies End-Use, CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• 3P Biopharmaceuticals
• Advanced Therapies
• Becton, Dickinson and Company (BD)
• Charles River Laboratories
• Corning Incorporated
• Cryo-Cell International
• Danaher Corporation
• Eppendorf AG
• Eurofins DiscoverX / SwissBio
• Fujifilm Irvine Scientific
• GE Healthcare Life Sciences (Cytiva)
• InvivoGen
• Lonza Group Ltd
• Merck KGaA (MilliporeSigma)
• Sartorius AG
• Sigma-Aldrich Corporation
• SCTbio
• Takara Bio Inc.
• Thermo Fisher Scientific
• WuXi AppTec / WuXi Biologics
• Cedarlane Laboratories

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Mammalian Cell Banking - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rapid Expansion of Biologics and Cell-Based Therapies Throws the Spotlight on Mammalian Cell Banking as a Foundational Bioprocessing Asset
  • Growth in Monoclonal Antibody and Vaccine Production Propels Demand for Master and Working Cell Banks with High Viability and Stability
  • Here's the Story: Regulatory Requirements from FDA and EMA Strengthen the Business Case for GMP-Compliant Cell Banking Protocols
  • Increased R&D in Cell and Gene Therapy Drives the Need for Customized, High-Fidelity Mammalian Cell Line Repositories
  • Here's How Cryopreservation Technology Advancements Are Enhancing Long-Term Storage and Post-Thaw Recovery Rates
  • Rising Outsourcing to CDMOs and CROs Spurs Demand for Scalable and Secure Cell Banking Infrastructure
  • Growth of Biosimilars and Personalized Medicine Expands the Use of Mammalian Cell Banks Across Smaller, Targeted Production Runs
  • Here's How Automation and Robotics Are Improving Consistency, Traceability, and Contamination Control in Cell Banking Workflows
  • Surge in Biomanufacturing Activity in Emerging Markets Accelerates Establishment of Regional Cell Banking Facilities
  • Here's How Advances in Cell Line Engineering Are Elevating the Importance of Cell Bank Characterization and Genetic Stability
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mammalian Cell Banking Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mammalian Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for TEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for TEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for TEP Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for IEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for IEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for IEP Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for SEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for SEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for SEP Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Academic & Research Institute End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Academic & Research Institute End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Academic & Research Institute End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for MCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for MCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for MCB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for WCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for WCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for WCB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for EoP Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for EoP Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for EoP Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for R&D CB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for R&D CB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for R&D CB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• JAPAN
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• CHINA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• EUROPE
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Mammalian Cell Banking by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• FRANCE
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• GERMANY
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Mammalian Cell Banking by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• INDIA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Mammalian Cell Banking by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Mammalian Cell Banking by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• AFRICA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030

IV. COMPETITION